Fed. Circ. Clears Amgen's Avastin Biosimilar In Notice Fight
Genetech's bid to block Amgen from marketing a biosimilar version of its blockbuster cancer drug Avastin fizzled out Monday, with a Federal Circuit panel upholding a Delaware federal judge's decision that...To view the full article, register now.
Already a subscriber? Click here to view full article